School of Life Science and Technology, Dalian University, Dalian 116622, China.
Carbohydr Polym. 2014 Jan 30;101:359-67. doi: 10.1016/j.carbpol.2013.09.055. Epub 2013 Sep 25.
The mixture of κ-neocarrabiose-sulfate, κ-neocarrahexaose-sulfate and κ-neocarraoctaose-sulfate were prepared from κ-carrageenan with enzyme. The anti-tumor and anti-angiogenic activity of obtained κ-carrageenan oligosaccharides (KOS), were explored. The results showed that KOS could inhibit the proliferation, migration and tube formation of ECV304 cells, and could inhibit the growth of new vessels in CAM model. KOS displayed strong anti-tumor activity in both S180 and MCF-7 xenograft models. Only human CD105 was detected in MCF-7 xenograft tumor, moreover KOS could decrease the growing of new blood vessels derived from tumor cell. Real-time PCR results showed that KOS could suppress the mRNA expression of human VEGF, bFGF, bFGFR and CD105 in MCF-7 xenograft tumor. All these results indicated that KOS has anti-tumor and anti-angiogenic activity in vivo and in vitro. Especially K has the potency to inhibit the differentiation of tumor cell to blood vessel endothelial cell.
κ-新卡拉胶六硫酸酯、κ-新卡拉胶八硫酸酯和 κ-新卡拉胶十硫酸酯的混合物是用酶从角叉菜胶中制备的。研究了所得角叉菜胶低聚糖(KOS)的抗肿瘤和抗血管生成活性。结果表明,KOS 能抑制 ECV304 细胞的增殖、迁移和管形成,能抑制 CAM 模型中新血管的生长。KOS 在 S180 和 MCF-7 异种移植模型中均显示出较强的抗肿瘤活性。仅在 MCF-7 异种移植瘤中检测到人类 CD105,而且 KOS 可减少源自肿瘤细胞的新血管的生长。实时 PCR 结果表明,KOS 可抑制 MCF-7 异种移植瘤中人类 VEGF、bFGF、bFGFR 和 CD105 的 mRNA 表达。这些结果表明,KOS 在体内和体外均具有抗肿瘤和抗血管生成活性。特别是 K 具有抑制肿瘤细胞向血管内皮细胞分化的潜力。